Wenkai Zhu

Shanghai, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Metabolic reprogramming promotes AR-V7 splicing via SRSF2 lactylation in castration-resistant prostate cancer.

Metabolic reprogramming promotes AR-V7 splicing via SRSF2 lactylation in castration-resistant prostate cancer.

Journal: Acta biochimica et biophysica Sinica

Published: May 24, 2026

Neutrophil extracellular traps-STC1 positive feedback loop promotes immune evasion and metastasis in bladder cancer.

Neutrophil extracellular traps-STC1 positive feedback loop promotes immune evasion and metastasis in bladder cancer.

Journal: Journal for immunotherapy of cancer

Published: November 03, 2025

Integrative single-cell and spatial transcriptomics with explainable AI reveal lethal prognostic axis in prostate cancer.

Integrative single-cell and spatial transcriptomics with explainable AI reveal lethal prognostic axis in prostate cancer.

Journal: NPJ digital medicine

Published: October 11, 2025

FOXA1-dependent NSUN2 facilitates the advancement of prostate cancer by preserving TRIM28 mRNA stability in a m5C-dependent manner.

FOXA1-dependent NSUN2 facilitates the advancement of prostate cancer by preserving TRIM28 mRNA stability in a m5C-dependent manner.

Journal: NPJ precision oncology

Published: October 07, 2024

Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression.

Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression.

Journal: Clinical and translational medicine

Published: May 12, 2022

Special issue "The advance of solid tumor research in China": Multi-omics analysis based on 1311 clear cell renal cell carcinoma samples identifies a glycolysis signature associated with prognosis and treatment response.

Special issue "The advance of solid tumor research in China": Multi-omics analysis based on 1311 clear cell renal cell carcinoma samples identifies a glycolysis signature associated with prognosis and treatment response.

Journal: International journal of cancer

Published: December 18, 2021

Prognostic Immunophenotyping Clusters of Clear Cell Renal Cell Carcinoma Defined by the Unique Tumor Immune Microenvironment.

Prognostic Immunophenotyping Clusters of Clear Cell Renal Cell Carcinoma Defined by the Unique Tumor Immune Microenvironment.

Journal: Frontiers in cell and developmental biology

Published: September 29, 2021

Integrative 5-Methylcytosine Modification Immunologically Reprograms Tumor Microenvironment Characterizations and Phenotypes of Clear Cell Renal Cell Carcinoma.

Integrative 5-Methylcytosine Modification Immunologically Reprograms Tumor Microenvironment Characterizations and Phenotypes of Clear Cell Renal Cell Carcinoma.

Journal: Frontiers in cell and developmental biology

Published: September 08, 2021

Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.

Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.

Journal: Frontiers in immunology

Published: July 01, 2021

m6A Regulator-Mediated Methylation Modification Model Predicts Prognosis, Tumor Microenvironment Characterizations and Response to Immunotherapies of Clear Cell Renal Cell Carcinoma.

m6A Regulator-Mediated Methylation Modification Model Predicts Prognosis, Tumor Microenvironment Characterizations and Response to Immunotherapies of Clear Cell Renal Cell Carcinoma.

Journal: Frontiers in oncology

Published: May 14, 2021

Fatty Acid Synthase Correlates With Prognosis-Related Abdominal Adipose Distribution and Metabolic Disorders of Clear Cell Renal Cell Carcinoma.

Fatty Acid Synthase Correlates With Prognosis-Related Abdominal Adipose Distribution and Metabolic Disorders of Clear Cell Renal Cell Carcinoma.

Journal: Frontiers in molecular biosciences

Published: September 25, 2020

Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.

Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.

Journal: The Prostate

Published: February 11, 2020

Showing 1-12 of 13

Last Updated: 09/26/2026